September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane
Author Affiliations & Notes
  • Shuhei Kimura
    Ophthalmology, Okayama University, Okayama City, Okayama pref., Japan
  • Yuki Morizane
    Ophthalmology, Okayama University, Okayama City, Okayama pref., Japan
  • Mio Hosokawa
    Ophthalmology, Okayama University, Okayama City, Okayama pref., Japan
  • Shinichiro Doi
    Ophthalmology, Okayama University, Okayama City, Okayama pref., Japan
  • Mika Hosogi
    Ophthalmology, Okayama University, Okayama City, Okayama pref., Japan
  • Fumio Shiraga
    Ophthalmology, Okayama University, Okayama City, Okayama pref., Japan
  • Footnotes
    Commercial Relationships   Shuhei Kimura, None; Yuki Morizane, None; Mio Hosokawa, None; Shinichiro Doi, None; Mika Hosogi, None; Fumio Shiraga, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4482. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shuhei Kimura, Yuki Morizane, Mio Hosokawa, Shinichiro Doi, Mika Hosogi, Fumio Shiraga; Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4482.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We assessed the efficacy of vitrectomy and inner limiting membrane (ILM) peeling, followed by anti-vascular endothelial growth factor (VEGF) therapy, in anti-VEGF-resistant age-related macular degeneration (AMD), due to vitreomacular traction (VMT) or epiretinal membranes (ERM).

Methods : We identified 6 patients with anti-VEGF-resistant AMD, due to VMT or ERMs, amongst 588 AMD patients (821 eyes) referred to Okayama University Hospital between February 2012 and May 2014. These patients underwent vitrectomy, which released the VMT (4 cases) or removed the ERM (2 cases), and ILM peeling. The regime used for intravitreal injections of anti-VEGF reagents after surgery was based on the severity of exudative changes in each patient. Preoperative and postoperative best-corrected visual acuities (BCVAs) and central retinal thicknesses (CRT) were compared.

Results : After vitrectomy and ILM peeling, all 6 patients responded to anti-VEGF therapy, and its use then maintained dry retinas. Mean BCVAs had not improve significantly (0.49 ± 0.28 before versus 0.43 ± 0.38 after surgery, P=0.538). However mean CRTs had significantly reduced after surgery, from 423 ± 83.5μm to 257 ± 75.8μm (P=0.0078).

Conclusions : Vitrectomy and ILM peeling, following by anti-VEGF therapy, may be a useful therapeutic option for anti-VEGF-resistant AMD, with VMT or ERMs.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×